Ultrasonographic guideline for thyroid nodules cytology: single institute experience

Kwang Min Kim, Joon Beom Park, Seong Joon Kang, Keum Seok Bae

Department of Surgery, The Armed Forces Capital Hospital, Seongnam, 
Department of Surgery, Yonsei University Wonju College of Medicine, Wonju, Korea

Purpose: The main issue with the current ultrasonography (US) guidelines is the overestimation of malignant and indeterminate nodules as they do not aid in making decisions to treat patients. To overcome this, new US guidelines for thyroid nodules that have been shown to be better correlated with cytologic results have been proposed. We also suggested specific indications for US-guided fine needle aspiration (FNA) using the new US guidelines.

Methods: Clinical and pathologic data from 925 patients and 1,419 thyroid nodules were retrospectively collected. All subjects underwent US- and US-guided FNA at Department of Surgery, Wonju Christian Hospital, between March 2010 and July 2011. Sensitivity, specificity, accuracy, positive predictive value (PPV), and negative predictive value (NPV) were calculated for both the current guidelines and the new guidelines.

Results: The accuracy, sensitivity, specificity, PPV, and NPV for the current guidelines in predicting malignancy were 24.1%, 99.3%, 62.2%, 25.0%, and 99.8%, respectively. The accuracy, sensitivity, specificity, PPV, and NPV for the new guidelines in predicting malignancy were 66.0%, 96.0%, 86.7%, 47.7%, and 99.4%, respectively.

Conclusion: The use of the new US guidelines allow for a more accurate and specific diagnosis and a better treatment plan than the current guidelines. Additionally, the use of the new FNA guidelines may help prevent unnecessary FNAs and promote cost-effective follow-up for patients.

Key Words: Ultrasonography, Guideline, Fine needle biopsy, Thyroid neoplasms

INTRODUCTION

Approximately 4% to 7% of all adults have thyroid nodules. Current epidemiologic data have shown that only 5% to 6.5% of the reported cases of thyroid nodules found by ultrasonography (US) are malignant and require further workup [1-3]. As the increasing prevalence of thyroid cancer increases, there is a need for a method that can identify malignant lesions that warrant further surgical treatment [4,5].

To date, fine needle aspiration (FNA) is not only the traditional diagnostic test for identifying malignant thyroid nodules [6], but also represents the “gold standard” preoperative test for diagnosing thyroid cancer. However, the sensitivity of FNA ranges from 65% to 98%, and the specificity from 72% to 98% [7]. The Bethesda classification system is typically used for indeterminate cytological results (atypical cells of undetermined significance, follicular ne-
plasm or suspicion of follicular neoplasm, suspicion of malignancy), which can further complicate the situation. Consequently, surgical resection is often required in indeterminate cases for a definitive diagnosis. Therefore, a comprehensive diagnostic algorithm using US findings is of interest to ensure accurate diagnosis and therapeutic planning, and to decrease diagnostic operative resections.

Neck US has long been used to evaluate the size, character and location of thyroid nodules, monitor nodule growth, and identify locoregional lymphadenopathy [6,8-10]. Many studies have classified specific US characteristics predictive of malignant thyroid nodules. For instance, current US characteristics are strongly correlated with malignancy include increased intranodular vascularity, the presence of micro- or macrocalcifications, a taller-than-wide pattern, hypoechogeneity, and speculated margins [11,12]. Although controversial, the current guidelines state that if any one of the above findings is observed, with the exception of intranodular vascularity, the nodule should be defined as suspicious for malignancy. In contrast, simple cysts defined as nodules that are predominantly cystic, cystic with comet tail artifacts, or nodules with a spongiform appearance are all likely to be benign. Indeterminate nodules are those that are not characteristic of either malignant or benign [11,13]. As the main issue with the current guidelines is the overestimation of malignant and indeterminate nodules, they are not useful in the decision-making process of a treatment plan as they result in unnecessary invasive procedures, including FNA and diagnostic thyroidectomy.

The purpose of this study is to address the disadvantages of the current guidelines by suggesting a new US-based guideline system for thyroid nodules. As well, with the use of these new guidelines, we discuss specific indications for US-guided FNA.

**METHODS**

Clinical and pathologic data were retrospectively collected from 925 patients with a total of 1,419 thyroid nodules, having undergone US- and US-guided FNA at Department of Surgery, Wonju Christian Hospital, between March 2010 and July 2011. All neck ultrasounds were performed by surgeons using high-frequency linear array transducers 7.5-13 MHz (Aloka Prosound α5, Hitachi Aloka Medical Ltd., Tokyo, Japan). US and FNA were performed by a surgeon under the supervision of three experienced endocrine surgeons.

Each patient was placed in the supine position with the neck extended. Examinations began with a transverse view of the neck from the supraclavicular to the submental area bilaterally, in order to evaluate the thyroid gland. Longitudinal views were also obtained with a color doppler to assess the vascularity of any nodules. After taking an image of the thyroid gland, the central and lateral compartment lymph nodes were assessed for any abnormality. FNA was performed by the same single surgeon following US evaluation.

The new US guidelines were established via discussions among experienced physicians who participated in this study. Each nodule was classified by standard US characteristics: suspicious for malignancy, indeterminate, probably benign. In total, 1,419 nodules were classified using both guidelines. From both guidelines, all classifications were correlated with the cytological results obtained by FNA. Benign cytological results were defined by the Bethesda classification system, including histopathology consistent with benign follicular nodule, Hashimoto thyroiditis, and subacute thyroiditis. The indeterminate category included results consistent with atypical cells of undetermined significance, follicular neoplasms, suspicion of follicular neoplasms, and suspicion of malignancies. Lastly, the malignant category was defined as all histopathology positive for malignancy. Sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) were calculated for US characteristics that suspicious for malignant nodules of both current and new guideline. Sensitivity, specificity, accuracy, PPV, and NPV were calculated for both current and new guidelines, with PASW ver. 18.0 (IBM Co., Armonk, NY, USA) used for statistical analysis.
RESULTS

The mean age of the 925 subjects was 51.87 years (range, 14 to 85 years), with 104 male and 821 female patients enrolled. The new guidelines divided nodules into three groups: suspicious for malignancy, indeterminate, and probably benign. Nodules suspicious for malignancy were defined using the following ultrasound patterns: nodules characterized by speculated margins that were markedly hypoechoic, taller-than-wide and markedly hypoechoic nodules, nodules with micro- or macrocalcifications that were markedly hypoechoic, and taller-than-wide nodules with micro- or macrocalcifications. Indeterminate lesions were defined as nodules exhibiting any one of the following patterns: markedly hypoechoic, a taller-than-wide pattern, a spiculated margin, and micro- or macrocalcifications. Nodules were classified as probably benign if the US characteristics were not consistent with either malignant or indeterminate features (Table 1).

Sensitivity of US characteristics that suggested malignancy by current guidelines generally was higher than that of the new guidelines. Specificity, PPV of US characteristics that suggested malignancy by new guidelines generally was higher than that of the current guidelines (Tables 2, 3).

After cytologic classification, 1,035 cases were found to be benign, 139 indeterminate, and 148 cases malignant. Using the current US-guidelines, 132 cases were defined as benign, 600 cases as indeterminate, and 590 cases suspicious for malignancy, with such results clearly indicating a large discrepancy. Based on the data presented here, the accuracy of this cross table is 24.1% (Table 4). After comparing the new US guidelines with cytological results, 726 cases were found to be benign, 298 cases indeterminate, and 298 cases malignant. The accuracy of this cross table was 66.0% (Table 5).

The relative sensitivity, specificity, PPV, and NPV for the current guidelines in predicting malignancy were 99.3%, 62.2%, 25.0%, and 99.8%, respectively. In comparison, the relative sensitivity, specificity, PPV, and NPV for the new

Table 1. New ultrasonography (US) guidelines for thyroid nodules

| US diagnosis                      | US characteristic                                                                 |
|----------------------------------|-----------------------------------------------------------------------------------|
| Suspicious for malignancy        | Spiculated margin and markedly hypoechoic                                          |
|                                  | Taller-than-wide pattern and markedly hypoechoic                                    |
|                                  | Micro- or macrocalcification and markedly hypoechoic                                |
|                                  | Taller-than-wide pattern and micro or macrocalcifications                           |
| Indeterminate                    | Taller-than-wide pattern                                                           |
|                                  | Markedly hypoechoic                                                               |
|                                  | Spiculated margin                                                                 |
|                                  | Micro- or macrocalcification                                                       |
| Probably benign                  | Neither malignant nor indeterminate US findings                                     |

Table 2. Ultrasonography (US) characteristics associated with thyroid cancer (current guideline)

| US characteristic | Sensitivity (%) | Specificity (%) | PPV (%) | NPV (%) |
|-------------------|----------------|----------------|---------|---------|
| Taller-than-wide pattern | 48.6          | 89.9           | 37.4    | 93.4    |
| Markedly hypoechoic          | 93.8          | 82.0           | 39.4    | 99.1    |
| Spiculated margin          | 48.6          | 92.5           | 44.7    | 93.5    |
| Micro- or macrocalcification | 52.1          | 84.7           | 29.8    | 93.4    |

PPV, positive predictive value; NPV, negative predictive value.

Table 3. Ultrasonography (US) characteristics associated with thyroid cancer (new guideline)

| US characteristic                                      | Sensitivity (%) | Specificity (%) | PPV (%) | NPV (%) |
|---------------------------------------------------------|----------------|----------------|---------|---------|
| Spiculated margin and markedly hypoechoic              | 45.9           | 86.6           | 62.6    | 93.5    |
| Taller-than-wide pattern and markedly hypoechoic       | 44.5           | 95.8           | 37.0    | 93.3    |
| Micro- or macrocalcification and markedly hypoechoic   | 47.9           | 96.1           | 60.3    | 93.7    |
| Taller-than-wide pattern and micro- or macrocalcifications | 20.1           | 97.3           | 43.9    | 90.4    |

PPV, positive predictive value; NPV, negative predictive value.
Table 4. Cross-table of the current guidelines and the cytologic results

| Current guidelines | Cytologic diagnosis |  |  |  |
|-------------------|---------------------|-----------------|-----------------|-----------------|
|                   | Benign              | Indeterminate   | Malignancy       | Total           |
| Benign            | 127                 | 5               | 0               | 132             |
| Indeterminate     | 554                 | 45              | 1               | 600             |
| Malignancy        | 354                 | 89              | 142             | 590             |
| Total             | 1,035               | 139             | 148             | 1,322           |

Table 5. Cross-table of the current guidelines and the cytologic results

| New guidelines | Cytologic diagnosis |  |  |  |
|----------------|---------------------|-----------------|-----------------|-----------------|
|                 | Benign              | Indeterminate   | Malignancy       | Total           |
| Benign          | 676                 | 50              | 0               | 726             |
| Indeterminate   | 238                 | 54              | 6               | 298             |
| Malignancy      | 121                 | 35              | 142             | 298             |
| Total           | 1,035               | 139             | 148             | 1,322           |

Table 6. Sensitivity, specificity, PPV, NPV for the current guidelines and the new guidelines

|                  | Current guidelines (%) | New guidelines (%) |
|------------------|------------------------|--------------------|
| Sensitivity      | 99.3                   | 96.0               |
| Specificity      | 62.2                   | 86.7               |
| PPV              | 25.0                   | 47.7               |
| NPV              | 99.8                   | 99.4               |

PPV, positive predictive value; NPV, negative predictive value.

guidelines in predicting malignancy were 96.0%, 86.7%, 47.7%, and 99.4%, respectively (Table 6).

DISCUSSION

To date, there have been several studies that examined specific US characteristics that accurately distinguished malignant from benign thyroid nodules. However, most of this data merely confirms US characteristics associated with malignancy [10,14-16]. Thus, studies have suggested developing new US guidelines using data from many cases to resolve this problem. Among the established guidelines; the most widely accepted definition of a lesion causing concern for malignancy if any of the aforementioned characteristics are present. In contrast, a simple cyst, which is predominantly a cystic lesion or a cystic nodule with comet tail artifacts, or a nodule with a spongiform appearance are characterized as probably benign. Indeterminate nodules include lesions with US findings that are known to be neither malignant nor benign. However, these particular guidelines are controversial as they tend to overestimate malignant and indeterminate nodules. Cooper et al. [17] reported that with the exception of suspicious cervical lymphadenopathy, a specific but insensitive finding, a combination of features made it possible to identify all malignant nodules, whereas a single US feature was unable to detect this. Therefore, studies proposed to use a combination of US characteristics with the purpose of resolving this problem by establishing a more precise US guideline. For instance, Horvath et al. [18] suggested a novel US reporting system for thyroid nodules, which the authors termed the Thyroid Imaging Reporting and Data System (TIRAD), and modeled after Breast Imaging-Reporting and Data System (BI-RADS). TIRAD stratifies lesions into six separate categories, each of which have a different risk of malignancy and specific treatment plan. However, this classification system is difficult to apply clinically due to its marked complexity [19]. Therefore, the intention to develop a more accurate, and simple guideline for thyroid nodules was explored.

Frates et al. [14] reported a range of sensitivity, specificity, PPV, and NPV of US characteristics suggested for malignancy by current guideline.

Sensitivity, specificity, PPV, and NPV of US characteristics suggesting malignancy by the current guidelines in this study was similar to that. Especially, sensitivity of marked hypoechogenecity is the highest. Generally, the new guidelines had better specificity and PPV than the current guidelines. Even though the current guidelines were more sensitive than the new guidelines, it seems to be the cause of lower sensitivity of the new guidelines than the current guidelines.

The results showed that the new guidelines had better accuracy, specificity, and PPV than the current guidelines, although the NPV was not significantly different between the two. Even though the current guideline system was more sensitive than the new guidelines, the new guidelines allowed for better diagnostic accuracy and proper
treatment planning. Also, the new guidelines were easily acquired easily when compared to TIRAD due to the complexity level. The principal issue associated with the new guidelines was the relatively low sensitivity. This may be explained by the three cases where the lesions were well-defined, taller-than-wide, and isoechoic with peripheral hypoechoic halos (Fig. 1), and three cases where the lesions were well-defined, oval-shaped, and markedly hypoechoic (Fig. 2). Together, these six nodules were diagnosed as “indeterminate” by the new guidelines and “suspicious for malignancy” by the current guidelines. To address this, nodules that were suspicious for malignancy, however categorized by the new guidelines as “indeterminate,” should be referred for FNA, particularly if they are taller-than-wide or markedly hypoechoic.

Recommendations regarding the indications for US-guided FNA are variable. Cause of absence single recommendation for FNA was concerned absence of single treatment guideline for thyroid cancer. Recently, many studies have recommended various treatment plans for thyroid cancer, although the issue of subcentimeter cancer remains controversial. Among the subcentimeter cancers, carcinomas smaller than 5 mm are associated with better survival rates and better recurrence rates at five years [20]. Ito et al. [21] reported similar results from an observational study involving such patients. Generally, the most recent studies recommended against the biopsy of nodules smaller than 5 mm in size as the evidence suggested that these lesions are often associated with a high rate of false

---

**Fig. 1.** (A, B) Well-defined taller-than-wide and isoechoic nodules with peripheral hypoechoic halo. These nodules resulted in the relatively low sensitivity of the new guidelines.

**Fig. 2.** Well-defined oval-shaped markedly hypoechoic nodules. These nodules resulted in the low sensitivity of the new guidelines.

**Fig. 3.** Algorithm for follow-up ultrasonography (US) and US-guided fine needle aspiration (FNA) according to US findings.
positive US characteristics yielding inadequate cytology [22,23]. Aggressive behavior has been reported in some subcentimeter thyroid carcinomas. When prophylactic central compartment node dissection was later performed, the node metastasis rate ranged from 30% to 80%, even though metastatic lymph nodes were not seen on preoperative imaging [24-26]. Based on this evidence, thyroidectomy and prophylactic central compartment node dissection is performed by most endocrine surgeons in Korea, regardless of lesion size. Given the current practice in Korea, we recommend performing FNA for all nodules varying in size that have US findings that are suspicious for malignancy as defined by the new guidelines, as well as lesions that are markedly hypoechoic, or have a taller-than-wide pattern. For nodules that are classified as indeterminate, especially micro- or macrocalcifications and speculated margins, FNA is recommended if the lesion diameter is larger than 1 cm. For benign appearing nodules, we recommend the lesion be followed by US (Fig. 3). These new FNA guidelines help avoid unnecessary FNAs and promote a cost-effective follow-up for patients.

In conclusion, the use of the new US guidelines allow for greater accuracy with higher specificity for diagnosis and treatment planning than the current guidelines. Additionally, the use of the new FNA guidelines based on the new US guidelines help avoid unnecessary FNAs and promotes cost-effective follow-up for patients.

CONFLICTS OF INTEREST

No potential conflict of interest relevant to this article was reported.

ACKNOWLEDGEMENTS

This work was supported by a research grant from Yonsei University Wonju College of Medicine (YUWCM-2011-62).

REFERENCES

1. Jabiev AA, Ikeda MH, Reis IM, Solorzano CC, Lew JI. Surgeon-performed ultrasound can predict differentiated thyroid cancer in patients with solitary thyroid nodules. Ann Surg Oncol 2009;16:3140-5.
2. Khati N, Adamson T, Johnson KS, Hill MC. Ultrasound of the thyroid and parathyroid glands. Ultrasound Q 2003; 19:162-76.
3. Chan BK, Desser TS, McDougall IR, Weigel RJ, Jeffrey RB Jr. Common and uncommon sonographic features of papillary thyroid carcinoma. J Ultrasound Med 2003;22: 1083-90.
4. Tan GH, Gharib H. Thyroid incidentalomas: management approaches to nonpalpable nodules discovered incidentally on thyroid imaging. Ann Intern Med 1997;126: 226-31.
5. Davies L, Welch HG. Increasing incidence of thyroid cancer in the United States, 1973-2002. JAMA 2006;295:2164-7.
6. Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL, Mandel SJ, et al. Management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 2006;16:109-42.
7. Tee YY, Lowe AJ, Brand CA, Judson RT. Fine-needle aspiration may miss a third of all malignancy in palpable thyroid nodules: a comprehensive literature review. Ann Surg 2007;246:714-20.
8. Gharib H, Papini E, Valcavi R, Baskin HJ, Crescenzi A, Dottorini ME, et al. American Association of Clinical Endocrinologists and Associazione Medici Endocrinologi medical guidelines for clinical practice for the diagnosis and management of thyroid nodules. Endocr Pract 2006;12:63-102.
9. Kouvaraki MA, Shapiro SE, Fornage BD, Edeiken-Monro BS, Sherman SI, Vassiloupoulou-Sellin R, et al. Role of preoperative ultrasonography in the surgical management of patients with thyroid cancer. Surgery 2003;134:946-54.
10. Koike E, Noguchi S, Yamashita H, Murakami T, Ohshima A, Kawamoto H, et al. Ultrasonographic characteristics of thyroid nodules: prediction of malignancy. Arch Surg 2001;136:334-7.
11. Moon WJ, Back JH, Jung SL, Kim DW, Kim EK, Kim JY, et al. Ultrasonography and the ultrasound-based management of thyroid nodules: consensus statement and recommendations. Korean J Radiol 2011;12:1-14.
12. Papini E, Guglielmi R, Bianchini A, Crescenzi A, Taccogna S, Nardi F, et al. Risk of malignancy in nonpalpable thyroid nodules: predictive value of ultrasound and color-Doppler features. J Clin Endocrinol Metab 2002;87:1941-6.
13. Moon WJ, Jung SL, Lee JH, Na DG, Baek JH, Lee YH, et al. Benign and malignant thyroid nodules: US differentiation–multicenter retrospective study. Radiology 2008; 247:762-70.
14. Frates MC, Benson CB, Charboneau JW, Cibas ES, Clark OH, Coleman BG, et al. Management of thyroid nodules detected at US: Society of Radiologists in Ultrasound consensus conference statement. Radiology 2005;237:794-800.
15. Iannuccilli JD, Cronan JJ, Monchik JM. Risk for malignancy of thyroid nodules as assessed by sonographic criteria: the need for biopsy. J Ultrasound Med 2004;23:1455-64.

16. Hoang JK, Lee WK, Lee M, Johnson D, Farrell S. US Features of thyroid malignancy: pearls and pitfalls. Radiographics 2007;27:847-60.

17. American Thyroid Association (ATA) Guidelines Task-force on Thyroid Nodules and Differentiated Thyroid Cancer, Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL, et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 2009;19:1167-214.

18. Horvath E, Majlis S, Rossi R, Franco C, Niedmann JP, Castro A, et al. An ultrasonogram reporting system for thyroid nodules stratifying cancer risk for clinical management. J Clin Endocrinol Metab 2009;94:1748-51.

19. Kwak JY, Han KH, Yoon JH, Moon HJ, Son EJ, Park SH, et al. Thyroid imaging reporting and data system for US features of nodules: a step in establishing better stratification of cancer risk. Radiology 2011;260:892-9.

20. Noguchi S, Yamashita H, Uchino S, Watanabe S. Papillary microcarcinoma. World J Surg 2008;32:747-53.

21. Ito Y, Miyauchi A, Inoue H, Fukushima M, Kihara M, Higashiyama T, et al. An observational trial for papillary thyroid microcarcinoma in Japanese patients. World J Surg 2010;34:28-35.

22. Kim DW, Lee EJ, Kim SH, Kim TH, Lee SH, Kim DH, et al. Ultrasound-guided fine-needle aspiration biopsy of thyroid nodules: comparison in efficacy according to nodule size. Thyroid 2009;19:27-31.

23. Mazzaferri EL, Sipos J. Should all patients with sub-centimeter thyroid nodules undergo fine-needle aspiration biopsy and preoperative neck ultrasonography to define the extent of tumor invasion? Thyroid 2008;18:597-602.

24. Attie JN, Setzin M, Klein I. Thyroid carcinoma presenting as an enlarged cervical lymph node. Am J Surg 1993;166:428-30.

25. Cady B. Surgery of thyroid cancer. World J Surg 1981;5:3-14.

26. Hay ID, Grant CS, van Heerden JA, Goellner JR, Ebersold JR, Bergstralh EJ. Papillary thyroid microcarcinoma: a study of 535 cases observed in a 50-year period. Surgery 1992;112:1139-46.